Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC)

Dirk Strumberg,M. E. Scheulen,R. A. Hilger,Jürgen Krauss,N. Marschner,F. Lordick,F. Bach,Dirk Reuter,L. Edler,K. Mross

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC)

2006

Dirk Strumberg
M. E. Scheulen
R. A. Hilger
Jürgen Krauss
N. Marschner
F. Lordick
F. Bach
Dirk Reuter
L. Edler
K. Mross

12504 Background: Nimotuzumab (OSAG101, Theraloc) is a humanized monoclonal antibody (mAb) that binds to the EGFR. In preclinical studies the antibody has shown potent antitumor activity. Based on ...

Keywords:

Metastatic pancreatic cancer
Anti-Epidermal Growth Factor Receptor
Nimotuzumab
EGFR Antibody
Internal medicine
Oncology
Monoclonal
Medicine
Pharmacokinetics
Monoclonal antibody
Pharmacology
locally advanced
Antibody
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations